Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH21 combined with targeted or immunotherapy in advanced solid tumors
NCT06322095Phase 2Recruiting
- Sponsor
- Genhouse Bio
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GH21 in solid tumor (advanced stage), sponsored by Genhouse Bio. Started Mar 2024; status: recruiting.
02
Drugs
GH21
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06322095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06322095.